Entries by PR Newswire

Acacia Pharma Initiates Phase 3 Combination Prophylaxis Study With APD421 in Post-Operative Nausea & Vomiting (PONV)

CAMBRIDGE, England, April 21, 2015 /PRNewswire/ — Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), the supportive care company developing products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard anti-emetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains […]

,

Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE

LOS ANGELES, April 21, 2015 /PRNewswire/ — Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Pradaxa’s maker, Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for its blood thinner to treat DVT and PE. According to PBR, Boehringer submitted a supplemental new drug application (sNDA) to the FDA in hopes that Pradaxa will be approved […]

Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia

SEATTLE, April 21, 2015 /PRNewswire/ — Seattle Children’s announced today that 20 of 22 patients treated thus far in a clinical trial using genetically reprogrammed T cells to treat relapsed acute lymphoblastic leukemia (ALL) have achieved complete remission, confirmed by highly sensitive tests designed to detect minute amounts of cancer cells. The 20 patients who […]

Protein identified that serves as a “break” on inflammation

MEMPHIS, Tenn., April 21, 2015 /PRNewswire-USNewswire/ — Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis (MS), colitis and other autoimmune disorders. St. Jude Children’s Research Hospital scientists led the study which appears today in the scientific journal Immunity. Investigators showed that […]

,

Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan

DUBLIN, April 21, 2015 /PRNewswire/ — Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE) today announced that its Board of Directors has unanimously rejected the unsolicited Proposal (the “Proposal”) from Mylan NV (“Mylan”) (NASDAQ: MYL), disclosed April 8, 2015, to acquire all of the outstanding shares of Perrigo for $205.00 per share. Following a thorough review, advised […]

,

Amgen’s First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48

THOUSAND OAKS, Calif., April 21, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2015. Key results include:   First Quarter 2015 Product Sales Performance Product Sales Detail by Product and Geographic Region   Operating Expense and Tax Rate Analysis, on an Adjusted Basis   Cash Flow and Balance […]

,

Perrigo Company plc Reports Record Fiscal Third Quarter Net Sales, Adjusted Net Income, Adjusted Margins, And Operating Cash Flow

DUBLIN, April 21, 2015 /PRNewswire/ — Third Quarter FY 2015 Highlights: Outlook: Perrigo Company plc (NYSE: PRGO; TASE) today announced results for its third quarter ended March 28, 2015. Chairman, President and CEO Joseph C. Papa commented, “Our results – highlighted by record fiscal third quarter net sales, adjusted net income, adjusted margins and operating cash […]

, ,

In Historic First, San Francisco Board of Supervisors Votes to Take Tobacco Out of Baseball

SAN FRANCISCO, April 21, 2015 /PRNewswire-USNewswire/ — Today the San Francisco Board of Supervisors unanimously passed an ordinance to prohibit use of all tobacco products – including smokeless tobacco – at all baseball venues and athletic fields within the city and county of San Francisco, including by fans and players at AT&T Park. San Francisco […]

,

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

TOKYO and CAMBRIDGE, Mass., April 21, 2015 /PRNewswire/ — Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration.  The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint […]